A medical expert examines an extreme body condition involving severe skin fragility and explains the underlying disorder.

The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic skin disorder recessive dystrophic epidermolysis bullosa.

MMP patients have a significantly increased risk of SCC, BCC, and NMSC, particularly with severe disease. The study analyzed data from over 117 million individuals, using propensity-score matching for ...

A study published in PNAS has found that for people with a rare form of ichthyosis, medications previously used to treat cancer could be repurposed for treatment. The study's lead author, Keith Choate ...

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the ...

Quoin Pharmaceuticals Ltd. has announced the filing of U.S. and International patent applications for new topical formulations of rapamycin aimed at treating rare diseases such as microcystic ...

Add Yahoo as a preferred source to see more of our stories on Google. SALT LAKE CITY (ABC4) — A Utah woman is sharing her story after she survived an incredibly rare and often fatal skin disorder ...

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...

Cutaneous mastocytosis is one of two types of mastocytosis, a rare disorder in which too many mast cells — a type of white blood cell that helps the immune system function properly — accumulate in the ...